DOCSLIB.ORG

Methods for Predicting the Survival Time of Patients Suffering from a Lung Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Methods for Predicting the Survival Time of Patients Suffering from a Lung Cancer THETWO TORTOITUUSN 20180252720A1ULLUM HOLATIN ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 / 0252720 A1 DIEU -NOSJEAN et al. (43 ) Pub. Date : Sep . 6 , 2018 (54 ) METHODS FOR PREDICTING THE Publication Classification SURVIVAL TIME OF PATIENTS SUFFERING (51 ) Int . Ci. FROM A LUNG CANCER GOIN 33 /574 ( 2006 .01 ) (71 ) Applicants : INSERM (INSTITUT NATIONAL ( 52 ) U . S . CI. DE LA SANTE ET DE LA CPC .. GOIN 33 /57423 (2013 . 01) ; GOIN 2800/ 52 RECHERCHE MEDICALE ) , Paris ( 2013 . 01 ) (FR ) ; UNIVERSITE PARIS DESCARTES , Paris ( FR ) ; SORBONNE UNIVERSITE , Paris (57 ) ABSTRACT (FR ) ; UNIVERSITE PARIS DIDEROT - PARIS 7 , Paris ( FR ) ; The present invention relates to methods for predicting the ASSISTANCE survival time of patients suffering from a lung cancer . In PUBLIQUE -HOPITAUX DE PARIS particular , the present invention relates to a method for (ADHP ) , Paris (FR ) predicting the survival time of a subject suffering from a lung cancer comprising the steps of i) quantifying the ( 72 ) Inventors: Marie - Caroline DIEU - NOSJEAN , density of regulatory T ( Treg ) cells in a tumor tissue sample Paris (FR ) ; Wolf Herdman obtained from the subject, ii ) quantifying the density of one FRIDMAN , Paris ( FR ) ; Catherine further population of immune cells selected from the group SAUTES - FRIDMAN , Paris ( FR ) ; consisting of TLS -mature DC or TLS - B cells or Tconv cells , Priyanka DEVI, Paris (FR ) CD8 + T cells or CD8 + Granzyme - B + T cells in said tumor tissue sample , iii ) comparing the densities quantified at steps (21 ) Appl. No. : 15/ 754 , 640 i ) and ii ) with their corresponding predetermined reference values and iv ) concluding that the subject will have a short ( 22 ) PCT Filed : Aug . 26 , 2016 survival time when the density of Treg cells is higher than its corresponding predetermined reference value and the ( 86 ) PCT No .: PCT/ EP2016 /070158 density of the further population of immune cells is lower $ 371 ( c ) ( 1 ) , than its corresponding predetermined reference value or ( 2 ) Date : concluding that the subject will have a long survival time Feb . 23 , 2018 when the density of Treg cells is lower than its correspond (30 ) Foreign Application Priority Data ing predetermined reference value and the density of the further population of immune cells is higher than its corre Aug . 27 , 2015 ( EP ) .. .. .. 15306318 .5 sponding predetermined reference value . TTT %OverallSurvival to Tregs lo ( n = 53 ) Tregs Hi( n = 190 ) P = 0 .0049 0 20 40 60 80 100 120 140 Time in months OverallSurvival. TLS Tregs to ( n = 58) TLS Tregs Hi ( n = 42 ) P = 0 . 0245 TTTTT 0 20 40 60 80 100 120 140 Tima In months Patent Application Publication Sep . 6 , 2018 Sheet 1 of 17 US 2018 / 0252720 A1 - o Urvi NOUBLIA . LOOPINI TLMJDUJJDLOOLID III . Ñ L Tregs lo ( n = 53 ) Tregs Hi (n = 190 ) P = 0 .0049 0 20 40 60 80 100 120 140 Time in months · . * * * D * * * * ' D' SO %OverallSurvival . DEI wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww ' TLS Tregs lo ( n = 58 ) IDEO TLS Tregs Hi ( n = 42 ) P = 0 . 0245 0 20 40 60 80 100 120 140 Time in months Figure 1A - B Patent Application Publication Sep . 6 , 2018 Sheet 2 of 17 US 2018 / 0252720 A1 0 ODBO OverallSurvival — — ??????????????? ??????????????? ??????????. wwwwwwwwwww w wwwwwwwwwwwwww IWWWWWWWWWWWW DC Hi ( n = 138) DC lo ( n = 105 ) P = 0 . 0002 O TT 0 20 40 60 80 100 120 140 Time in months WWWWWWWWW o %OverallSurvival www ** ** * * ** * * ** * * * * * * * * ** ** * * * * * * * -. - to - HIDC / la Tregs ( n = 26 ) HIDC / Hi Tregs ( n = 11Z ) LO DC / LO Tregs ( n = 27 ) LODC / Hi Tregs ( n = 78 ) P < 0 .0001 0 20 40: 60 80 100 120 140 Time in months Figures 1C - D Patent Application Publication Sep . 6 , 2018 Sheet 3 of 17 US 2018 / 0252720 A1 P . e . www . .LLLLLLL . * * * * * * * * * ?????????????? ” ??? . OverallSurvival . wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww . B cell Hi ( n = 172 ) . B cell lo ( n = 71 ) . P = 0 . 0020 0 20 40 60 80 100 120 140 Time in months IIIIIIIIII IIIIIII IIIIIIIIIIII IBIIIIIIII %OverallSurvival HiB cells / lo Tregs ( n = 31) HiB cells / Hi Tregs ( n = 141 ) LOB cells / Lo Tregs ( n = 22 ) LOB cells / Hi Tregs ( n = 49 ) P < 0 .0001 T 0 20 40 60 80 100 120 140 Time in months Figure 1 E - F Patent Application Publication Sep . 6 , 2018 Sheet 4 of 17 US 2018 / 0252720 A1 64 IIIIIIII E IEEELD T . DIRIBEROI BÖLIBIIIIIIIII 13 OverallSurvival ??????????? À CD8 Hi ( n = 178 ) CD8 lo ( n = 63 ) P = 0 . 0027 TTTTTTTTTTT 0 20 40 60 80 100 120 140 0 IIIIIIIIIIIIIIIII IIIIIII %OverallSurvival to Hi CD8 /lo Tregs ( n = 37 ) Hi CD8 / Hi Tregs ( n = 141 ) Lo CD8 / Lo Tregs ( n = 16 ) o Lo CD8 / Hi Tregs ( n = 47 ) P = 0 . 0002 20 40 60 80 100 120 140 Time in months Figures 1G - H Patent Application Publication Sep . 6 , 2018 Sheet 5 of 17 US 2018 / 0252720 A1 Optimal cut- off value 1 . 12] . + + + + . T . 0.1 . + . + . + 0 .05 . + . + anjead + + . + . + + + + + + . + 100 . + . + . + . + . + . + . + . + . 898 . 7939 cells /mm2 . 0.001 . IIIIIIIIIIIIIIIIII I wo OZ+L 2300- . 008 2900 Density of CD3 + T cells ( cells /mm2 ) Optimal cut - off value - tait elen k - 01 - 0 .05 * 0.01 ILETILI+T11T1P1II1III11ETTIITTI ** p-value 11111111111 - 04000118- - -. 1e-05 21. 99746 cells /mm ? UTWELL L8L . Density of FoxP3+ Treg cells (cells / mm2 ) Figures 2A - B Patent Application Publication Sep . 6 , 2018 Sheet 6 of 17 US 2018 / 0252720 A1 Optimal cut- off value Ww.V RARLASERRISSURMARN A SS. 0.1 3 W . AWI Www Way Town where s ubteran 0 . 05 . MITTTTTTTT . W : 0.01 SHIRASHIFRA 001.0 L11MLIMILO .L 16-04 17 . 94117 cells /mm2 Density of the CD3 + T cells : Tregs ratio ( cells / mm2) Optimal cut- off value www ace. HO . * * * : . MIX . : : s it * * . t t . s . 0 . 05 . * anjeu-d 100 * * : n 1000 . i : 10-01 12 . 41506 cellselefon /mm2 LLLLLLLLLLLLL Density of the CD8 + T cells : Tregs ratio ( cells /mm2 ) Figures 2C - D Patent Application Publication Sep . 6 , 2018 Sheet 7 of 17 US 2018 / 0252720 A1 Optimal cut- off value L AMINA . 1SASHAUNAS 0.1 *withthe 11 : 01 TI . W . W e will be ablew ith Wale Wut wa linew ith p-value . .the ,. 0.001 . 0 . 06297162 cells /mm2 1e-04 . LLLLLLLLLLLLLLL Density of mDC cells : Treg cells (cells /mm2 ) horen en meer Optimal cut- off - value MITT MMWWWW WWW content contre este comentariosm sobre esteen esemegen : 0 .05 # D-value 0.01 0.001 LLL #DOT . LAALALLAAMAALAALUSVAATSULANTAIWAN 041e- 3.47.. 127. 0348 cells /mm2 Polda 1100- -1400 DensityDensite of the tres Tregsegs in horis fcellarells /mm2 m2) Figures 2E - F Patent Application Publication Sep . 6 , 2018 Sheet 8 of 17 US 2018 / 0252720 A1 . .. .. Piw ow . .wwwwwwwwwwwwwwwww %OverallSurvival Wwwx . www .w . w .w . www .w . www . www . www . www .wwwwwwwwwwwwwwwwww wwwww E USTATISTIMITS cD3 Hi ( n = 87 ) CD3 lo ( n = 156 ) P = 0 . 0073 p por r op 0 20 40 60 80 100 120 140 Time in months SIIRRITOTT . WSOUNDSYSSESSOUSCOUSSSSSSSSSSSSSSSSSSSS %OverallSurvival AKASSAR W . .. M SHAGANDA . CD3: FoxP3 ratio lo (n = 152) P = 0 . 0008 W 0 20 40 60 80 100 120 140 Time in months Figure 3 A - B Patent Application Publication Sep . 6 , 2018 Sheet 9 of 17 US 2018 / 0252720 A1 JUD . O OOOOOO . .. ) %QuerallSurvival . : . DC :FoxP3 ratio Hi (n = 66 ) DC : FoxP3 ratio lo ( n = 177 ) P = 0 . 0003 ?????. ???? ? ? ??? ???? ???? ?????? ?????? . ??? ?? ????? . ? ?? ????????????? ? ?????? ? o 20 40 60 80 100 120 140 Time in months . 0 . 0 . ILLIUS JOO . %OverallSurvival . .. ** * . CD8 :FoxP3 ratio Hi (n = 77 ) . CD8: FoxP3 ratio lo (n = 164 ) P = 0 .0005 0 0 20 40 60 80 100 120 140 Time in months Figure 3C - D Patent Application Publication Sep . 6 , 2018 Sheet 10 of 17 US 2018/ 0252720 A1 ? ? . - . .. - . - - - - - - -- 2 Tregs- Low ( n = 101 ) - 1 - Tregs Hi ( n = 237) all - All patients ( n = 338) P = 0 . 004 ?? : : : : ! (%)so ? ? ? ? ? ? ?? . r ? ? ? ? ??8?9???? ?? ? ? ??? ? 20 40 0 " " " 80" 1 100 120 Time ( months) B 2 - TLS- Tregs Low ( n = 58 ) -L. 1 - TLS - Tregs Hi ( n = 42) all - - All patients( n = 100) P = 0. 024 (%)so ??8090??? - ? ? ? LEl . III ? ? ?? ????? ?? ?? ? ? ? ? ? ? 20 40 60 80 100 120 Time ( months) Figure 4 A - B Patent Application Publication Sep . 6 , 2018 Sheet 11 of 17 US 2018 / 0252720 A1 o 1.0 - CD3 Hi ( n = 94) ] 2 – CD3 Low ( n = 244 ) 0.8 NH all - All Patients (n = 338) P = 0 .002 0.6 modo RA (%)SO Mwstgraukti?tinggit 1 .44 TEHT IH ! em * * *MW Hort 1 0.4 thangrant that 1 TEN111 ! + 2 0.2 HI 0. TTTT20 40 60 80 100 120 Time( months ) 1.0 TTTTTT 11111111111111111 0.8 mwater tanker off # 1 0.6 (%)50 MTTTILL HHHHHHHHHHIHI + H + + + + LI: 40. Cp3St Hl / Tregs Low ( n = 19 ) ht - H3all CD3 Hi/ Trags Hi (n = 75 ) 2 20. CD3 Low / Trags Low ( n = 82 ) 3 2 with + 4 IT CD3 Low / Trags HI ( n = 182 ) 4 All Pationts ( n = 338 ) P < 0 . 001 0. 0 20 40 60 80 100 120 Time (months ) Figure 4 C - D Patent Application Publication Sep . 6 , 2018 Sheet 12 of 17 US 2018 / 0252720 A1 E 1.0 1 - CD8 Hi ( n = 265) 2 -- CD8 Low (n = 70 ) 0.8 all - AllPatients ( n = 335 ) P < 0 . 001 0.6 OS(%) HILTILL 4111111 IT 0.4 * 1 all 0.2 barrisThe truthtorney fathe + # 2 0. 20 40 60 80 100 120 Time (months ! 1.0 1 B6Hit Fregs to th - bot F CD8 Hi/ Tregs Hi ( n = 197 ) CD8 Low / Tregs Low ( n = 32 ) 0.8 CDB Low / Tregs Hi ( n = 38 ) All Patients ( n = 33B ) 0.6 05(%) memoration that ITH + THrrr # 1 0.4 to benght 0.2 P << 0 . 001 0. TT 20 40 60 80 100 120 Time( months ) Figure 4 E - F Patent Application Publication Sep . 6 , 2018 Sheet 13 of 17 US 2018 /0252720 A1 G 1.0 1 - DC Hi ( n = 187) 2 - DC Low (n = 151) 0.8 all - All Patients ( n = 338 ) P < 0 .
Load more

Recommended publications
  • Lonidamine Induces Apoptosis in Drug-Resistant Cells Independently of the P53 Gene
    Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. D Del Bufalo, … , A Sacchi, G Zupi J Clin Invest. 1996;98(5):1165-1173. https://doi.org/10.1172/JCI118900. Research Article Lonidamine, a dichlorinated derivative of indazole-3-carboxylic acid, was shown to play a significant role in reversing or overcoming multidrug resistance. Here, we show that exposure to 50 microg/ml of lonidamine induces apoptosis in adriamycin and nitrosourea-resistant cells (MCF-7 ADR(r) human breast cancer cell line, and LB9 glioblastoma multiform cell line), as demonstrated by sub-G1 peaks in DNA content histograms, condensation of nuclear chromatin, and internucleosomal DNA fragmentation. Moreover, we find that apoptosis is preceded by accumulation of the cells in the G0/G1 phase of the cell cycle. Interestingly, lonidamine fails to activate the apoptotic program in the corresponding sensitive parental cell lines (ADR-sensitive MCF-7 WT, and nitrosourea-sensitive LI cells) even after long exposure times. The evaluation of bcl-2 protein expression suggests that this different effect of lonidamine treatment in drug-resistant and -sensitive cell lines might not simply be due to dissimilar expression levels of bcl-2 protein. To determine whether the lonidamine-induced apoptosis is mediated by p53 protein, we used cells lacking endogenous p53 and overexpressing either wild-type p53 or dominant-negative p53 mutant. We find that apoptosis by lonidamine is independent of the p53 gene. Find the latest version: https://jci.me/118900/pdf
    [Show full text]
  • Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide KAVINDRA NATH 1, DAVID S
    ANTICANCER RESEARCH 37 : 3413-3421 (2017) doi:10.21873/anticanres.11708 Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide KAVINDRA NATH 1, DAVID S. NELSON 1, JEFFREY ROMAN 1, MARY E. PUTT 2, SEUNG-CHEOL LEE 1, DENNIS B. LEEPER 3 and JERRY D. GLICKSON 1 Departments of 1Radiology and 2Biostatistics & Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, U.S.A.; 3Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, U.S.A. Abstract. Background/Aim: Since temozolomide (TMZ) is stages. However, following recurrence with metastasis, the activated under alkaline conditions, we expected lonidamine prognosis is poor. Mutationally-activated BRAF is found in (LND) to have no effect or perhaps diminish its activity, but 40-60% of all melanomas with most common substitution of initial results suggest it may actually enhance either or both valine to glutamic acid at codon 600 (p. V600E) (3). Overall short- and long-term activity of TMZ in melanoma xenografts. survival is approaching two years using agents that target this Materials and Methods: Cohorts of 5 mice with subcutaneous mutation (4, 5). MEK, RAS and other signal transduction xenografts ~5 mm in diameter were treated with saline inhibitors, in combination with mutant BRAF inhibitors, have (control (CTRL)), LND only, TMZ only or LND followed by been used to deal with melanoma resistance to these agents TMZ at t=40 min (time required for maximal tumor (6). Treatment with anti-programmed death-1 (PD-1) acidification). Results: Mean tumor volume for LND+TMZ for checkpoint inhibitor immunotherapy currently produces the period between 6 and 26 days was reduced compared to durable response in about 25% of melanoma patients (7-10).
    [Show full text]
  • Targeting the Mitochondrial Metabolic Network: a Promising Strategy in Cancer Treatment
    International Journal of Molecular Sciences Review Targeting the Mitochondrial Metabolic Network: A Promising Strategy in Cancer Treatment Luca Frattaruolo y , Matteo Brindisi y , Rosita Curcio, Federica Marra, Vincenza Dolce and Anna Rita Cappello * Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Via P. Bucci, 87036 Rende (CS), Italy; [email protected] (L.F.); [email protected] (M.B.); [email protected] (R.C.); [email protected] (F.M.); [email protected] (V.D.) * Correspondence: [email protected] These authors contributed equally and should be considered co-first authors. y Received: 31 July 2020; Accepted: 19 August 2020; Published: 21 August 2020 Abstract: Metabolic reprogramming is a hallmark of cancer, which implements a profound metabolic rewiring in order to support a high proliferation rate and to ensure cell survival in its complex microenvironment. Although initial studies considered glycolysis as a crucial metabolic pathway in tumor metabolism reprogramming (i.e., the Warburg effect), recently, the critical role of mitochondria in oncogenesis, tumor progression, and neoplastic dissemination has emerged. In this report, we examined the main mitochondrial metabolic pathways that are altered in cancer, which play key roles in the different stages of tumor progression. Furthermore, we reviewed the function of important molecules inhibiting the main mitochondrial metabolic processes, which have been proven to be promising anticancer candidates in recent years. In particular, inhibitors of oxidative phosphorylation (OXPHOS), heme flux, the tricarboxylic acid cycle (TCA), glutaminolysis, mitochondrial dynamics, and biogenesis are discussed. The examined mitochondrial metabolic network inhibitors have produced interesting results in both preclinical and clinical studies, advancing cancer research and emphasizing that mitochondrial targeting may represent an effective anticancer strategy.
    [Show full text]
  • Nath, K., Guo, L., Nancolas, B., Nelson, D. S., Shestov, A. A., Lee, S- C., Roman, J., Zhou, R., Leeper, D
    Nath, K., Guo, L., Nancolas, B., Nelson, D. S., Shestov, A. A., Lee, S- C., Roman, J., Zhou, R., Leeper, D. B., Halestrap, A. P., Blair, I. A., & Glickson, J. D. (2016). Mechanism of antineoplastic activity of lonidamine. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1866(2), 151-162. https://doi.org/10.1016/j.bbcan.2016.08.001 Peer reviewed version License (if available): CC BY-NC-ND Link to published version (if available): 10.1016/j.bbcan.2016.08.001 Link to publication record in Explore Bristol Research PDF-document This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at http://dx.doi.org/10.1016/j.bbcan.2016.08.001. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Mechanism of Antineoplastic Activity of Lonidamine Kavindra Nath1, Lili Guo2, Bethany Nancolas3, David S. Nelson1, Alexander A Shestov1, Seung-Cheol Lee1, Jeffrey Roman1, Rong Zhou1, Dennis B. Leeper4, Andrew P. Halestrap3, Ian A. Blair2 and Jerry D. Glickson1 Departments of Radiology1 and Center of Excellence in Environmental Toxicology, and Department of Systems Pharmacology and Translational Therapeutics2, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA, School of Biochemistry3, Biomedical Sciences Building, University of Bristol, BS8 1TD, UK.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Supplementary Table 1 Mean Viability Values for Each Cell Line for Each Compound Tested in the Small Molecule Screen
    Supplementary Table 1 Mean viability values for each cell line for each compound tested in the small molecule screen. A value of "1" represents a hypothetical, perfectly flat line (no effect). Drug GTL-16 GTL-16_A GTL-16_B GTL-16_C GTL-16_D GTL-16_E GTL-16_F GTL-16_G GTL-16_H GTL-16_I GTL-16_J GTL-16_K (S)-Citalopram Oxalate 0.94311374 0.98629332 0.95815778 0.9297682 0.94129628 0.97543865 0.92876703 0.94308692 0.97087634 0.92498189 1.03652668 2-Ethyl-2-thiopseudourea, HBr 0.9926737 1.02483487 1.04627788 1.01238942 1.01124644 0.99179834 1.03981841 1.03206468 1.07888484 0.95669609 1.03375137 1.00257194 2-methoxyestradiol 0.95743567 1.02442777 0.96874416 0.95701057 0.96000141 0.9319331 0.96175575 0.98632097 0.97543859 1.07065523 0.9810608 1.00528908 3-Isobutyl-1-methyl-xanthine 1.07753563 0.90621853 0.91486669 0.88967401 1.00929224 0.87712008 0.86304086 0.84795183 0.8218478 0.80844665 0.86385089 0.88111275 5-FU 0.5692879 0.58485568 0.59111845 0.66370136 0.60502565 0.52588075 0.61204398 0.55819142 0.57166713 0.44119668 0.61203408 0.61352444 6-aminonicotinimide 0.67580861 0.74962443 0.74297309 0.78548056 0.69875711 0.76253933 0.72148764 0.75038254 0.72102743 0.74534333 0.77091813 A-1331852 0.93531603 0.90417945 0.94313675 0.92505068 0.94545311 0.96834266 0.88789237 0.93844146 0.94623333 0.95265883 0.84359944 0.98073947 a-cyano-4-OH-cinnamate (CHCA) 0.9952172 0.98906165 0.99838293 1.01442099 0.99624294 1 0.98471749 1.0049547 1.02723098 0.9742409 0.9819023 1.0257504 A922500 0.87694919 0.97097522 0.94563395 0.96351612 0.90027344 0.97543859 0.95685369
    [Show full text]
  • Exploring the Anti-Leukemic Effect of the Combination Treatment with Valproic Acid, Lonidamine and Mycophenolate Mofetil in Acute Myeloid Leukemia
    P a g e | 1 Exploring the anti-leukemic effect of the combination treatment with Valproic acid, Lonidamine and Mycophenolate mofetil in acute myeloid leukemia Carina Hinrichs Master`s Degree This thesis is submitted in partial fulfilment of the requirements for the degree of Master of Science in Medical Biology – Medical Cell Biology. The work was conducted at Section for Hematology, Clinical Institute II, University of Bergen. Department of Biomedicine and Department of Clinical Science University of Bergen, Norway June 2015 1 P a g e | 2 Acknowledgement I would like to first and foremost sincerely acknowledge my head supervisor Dr. Rakel Brendsdal Forthun for inviting me to the Translational Hematology and Oncology Group at the Department of Clinical Science and University of Bergen. Not only has her continued support and encouragement kept me motivated and saved a lot of sleepless nights, but her scientific knowledge and thoroughly proofreading also inspired me to strive for a better understanding of my thesis and cancer research. I would also like to thank my co-supervisor Professor Bjørn Tore Gjertsen for including me into his research group and into the scientific environment. I truly appreciate the way Bjørn Tore Gjertsen has guided me through my studies and the attention he has given me and my work. I am most thankful to all of the colleagues of the Gjertsen laboratory for their good advises, technical help and especially for lighten up the scientific workplace. Wenche Eilifsen and Siv Lise Bedringaas are appreciated for their helping hand they have given me when I was “lost” in the laboratory.
    [Show full text]
  • Multistage Delivery of Active Agents
    111111111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (io) Patent No.: US 10,143,658 B2 Ferrari et al. (45) Date of Patent: Dec. 4, 2018 (54) MULTISTAGE DELIVERY OF ACTIVE 6,355,270 B1 * 3/2002 Ferrari ................. A61K 9/0097 AGENTS 424/185.1 6,395,302 B1 * 5/2002 Hennink et al........ A61K 9/127 (71) Applicants:Board of Regents of the University of 264/4.1 2003/0059386 Al* 3/2003 Sumian ................ A61K 8/0241 Texas System, Austin, TX (US); The 424/70.1 Ohio State University Research 2003/0114366 Al* 6/2003 Martin ................. A61K 9/0097 Foundation, Columbus, OH (US) 424/489 2005/0178287 Al* 8/2005 Anderson ............ A61K 8/0241 (72) Inventors: Mauro Ferrari, Houston, TX (US); 106/31.03 Ennio Tasciotti, Houston, TX (US); 2008/0280140 Al 11/2008 Ferrari et al. Jason Sakamoto, Houston, TX (US) FOREIGN PATENT DOCUMENTS (73) Assignees: Board of Regents of the University of EP 855179 7/1998 Texas System, Austin, TX (US); The WO WO 2007/120248 10/2007 Ohio State University Research WO WO 2008/054874 5/2008 Foundation, Columbus, OH (US) WO WO 2008054874 A2 * 5/2008 ............... A61K 8/11 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Akerman et al., "Nanocrystal targeting in vivo," Proc. Nad. Acad. Sci. USA, Oct. 1, 2002, 99(20):12617-12621. (21) Appl. No.: 14/725,570 Alley et al., "Feasibility of Drug Screening with Panels of Human tumor Cell Lines Using a Microculture Tetrazolium Assay," Cancer (22) Filed: May 29, 2015 Research, Feb.
    [Show full text]
  • Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences
    cancers Article Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences Stefanie Lietke 1,2,† , Michael Schmutzer 1,2,† , Christoph Schwartz 1,3, Jonathan Weller 1,2 , Sebastian Siller 1,2 , Maximilian Aumiller 4,5 , Christian Heckl 4,5 , Robert Forbrig 6, Maximilian Niyazi 2,7, Rupert Egensperger 8, Herbert Stepp 4,5 , Ronald Sroka 4,5 , Jörg-Christian Tonn 1,2, Adrian Rühm 4,5,‡ and Niklas Thon 1,2,*,‡ 1 Department of Neurosurgery, University Hospital, LMU Munich, 81377 Munich, Germany 2 German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany 3 Department of Neurosurgery, University Hospital Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria 4 Laser-Forschungslabor, LIFE Center, University Hospital, LMU Munich, 81377 Munich, Germany 5 Department of Urology, University Hospital, LMU Munich, 81377 Munich, Germany 6 Institute for Clinical Neuroradiology, University Hospital, LMU Munich, 81377 Munich, Germany 7 Department of Radiation Oncology, University Hospital, LMU Munich, 81377 Munich, Germany 8 Center for Neuropathology and Prion Research, University Hospital, LMU Munich, 81377 Munich, Germany * Correspondence: [email protected]; Tel.: +49-89-4400-0 † Both authors contributed equally. ‡ This study is guided by AR and NT equally thus both serve as shared last authors. Citation: Lietke, S.; Schmutzer, M.; Schwartz, C.; Weller, J.; Siller, S.; Simple Summary: Malignant glioma has a poor prognosis, especially in recurrent situations. Intersti- Aumiller, M.; Heckl, C.; Forbrig, R.; tial photodynamic therapy (iPDT) uses light delivered by implanted light-diffusing fibers to activate Niyazi, M.; Egensperger, R.; et al. a photosensitizing agent to induce tumor cell death. This study examined iPDT for the treatment Interstitial Photodynamic Therapy of malignant glioma recurrences.
    [Show full text]
  • Antigen Binding Protein and Its Use As Addressing Product for the Treatment of Cancer
    (19) TZZ 58Z9A_T (11) EP 2 589 609 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.05.2013 Bulletin 2013/19 C07K 16/28 (2006.01) (21) Application number: 11306416.6 (22) Date of filing: 03.11.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB •Beau-Larvor, Charlotte GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 74520 Jonzier Epagny (FR) PL PT RO RS SE SI SK SM TR • Goetsch, Liliane Designated Extension States: 74130 Ayze (FR) BA ME (74) Representative: Regimbeau (83) Declaration under Rule 32(1) EPC (expert 20, rue de Chazelles solution) 75847 Paris Cedex 17 (FR) (71) Applicant: PIERRE FABRE MEDICAMENT 92100 Boulogne-Billancourt (FR) (54) Antigen binding protein and its use as addressing product for the treatment of cancer (57) The present invention relates to an antigen bind- of Axl, being internalized into the cell. The invention also ing protein, in particular a monoclonal antibody, capable comprises the use of said antigen binding protein as an of binding specifically to the protein Axl as well as the addressing product in conjugation with other anti- cancer amino and nucleic acid sequences coding for said pro- compounds,such as toxins, radio- elements ordrugs, and tein. From one aspect, the invention relates to an antigen the use of same for the treatment of certain cancers. binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization EP 2 589 609 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 589 609 A1 Description [0001] The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein.
    [Show full text]
  • Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy
    International Journal of Molecular Sciences Review Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy Wentao Xia, Zixuan Tao, Bin Zhu, Wenxiang Zhang , Chang Liu , Siyu Chen * and Mingming Song * School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China; [email protected] (W.X.); [email protected] (Z.T.); [email protected] (B.Z.); [email protected] (W.Z.); [email protected] (C.L.) * Correspondence: [email protected] (S.C.); [email protected] (M.S.); Tel.: +86-25-8618-5645 (M.S.) Abstract: Cancer is one of the primary causes of worldwide human deaths. Most cancer patients receive chemotherapy and radiotherapy, but these treatments are usually only partially efficacious and lead to a variety of serious side effects. Therefore, it is necessary to develop new therapeutic strategies. The emergence of nanotechnology has had a profound impact on general clinical treatment. The application of nanotechnology has facilitated the development of nano-drug delivery systems (NDDSs) that are highly tumor selective and allow for the slow release of active anticancer drugs. In recent years, vehicles such as liposomes, dendrimers and polymer nanomaterials have been considered promising carriers for tumor-specific drug delivery, reducing toxicity and improving biocompatibility. Among them, polymer nanoparticles (NPs) are one of the most innovative methods of non-invasive drug delivery. Here, we review the application of polymer NPs in drug delivery, gene therapy, and early diagnostics for cancer therapy. Citation: Xia, W.; Tao, Z.; Zhu, B.; Keywords: polymer nanocarriers; cancer therapy; drug delivery Zhang, W.; Liu, C.; Chen, S.; Song, M.
    [Show full text]
  • Analytics for Improved Cancer Screening and Treatment John
    Analytics for Improved Cancer Screening and Treatment by John Silberholz B.S. Mathematics and B.S. Computer Science, University of Maryland (2010) Submitted to the Sloan School of Management in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Operations Research at the MASSACHUSETTS INSTITUTE OF TECHNOLOGY September 2015 ○c Massachusetts Institute of Technology 2015. All rights reserved. Author................................................................ Sloan School of Management August 10, 2015 Certified by. Dimitris Bertsimas Boeing Leaders for Global Operations Professor Co-Director, Operations Research Center Thesis Supervisor Accepted by . Patrick Jaillet Dugald C. Jackson Professor Department of Electrical Engineering and Computer Science Co-Director, Operations Research Center 2 Analytics for Improved Cancer Screening and Treatment by John Silberholz Submitted to the Sloan School of Management on August 10, 2015, in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Operations Research Abstract Cancer is a leading cause of death both in the United States and worldwide. In this thesis we use machine learning and optimization to identify effective treatments for advanced cancers and to identify effective screening strategies for detecting early-stage disease. In Part I, we propose a methodology for designing combination drug therapies for advanced cancer, evaluating our approach using advanced gastric cancer. First, we build a database of 414 clinical trials testing chemotherapy regimens for this cancer, extracting information about patient demographics, study characteristics, chemother- apy regimens tested, and outcomes. We use this database to build statistical models to predict trial efficacy and toxicity outcomes. We propose models that use machine learning and optimization to suggest regimens to be tested in Phase II and III clinical trials, evaluating our suggestions with both simulated outcomes and the outcomes of clinical trials testing similar regimens.
    [Show full text]